Asian Spectator

Times Advertising

Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China

  • UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk
  • In a placebo-controlled phase 2 trial in Chinese people with overweight or obesity, UBT251 led to a statistically significant mean weight loss of up to 19.7% after 24 weeks
  • UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies.

Magazine

Angka deforestasi meningkat, bayang-bayang krisis dan bencana mengintai

● Deforestasi Indonesia meningkat tajam, terjadi di semua pulau besar, terutama Kalimantan dan Papua.● Lonjakan ekstrem turut terjadi di Aceh, Sumatera Utara, dan Sumatera Barat, berkorela...

Harga BBM ditahan: Boleh berlega hati atau hanya menunda masalah?

CC BYDampak nyata Perang Amerika Serikat dan Iran masih berlanjut, penutupan selat hormuz oleh pihak Iran melambungkan harga minyak mentah hingga US$100 per barel (senilai Rp17 juta) dan diperkirakan ...

Riset: Proyek geotermal di sejumlah daerah lanjut terus meski banyak melanggar HAM

● Terdapat banyak pelanggaran HAM dalam pengembangan proyek geotermal di Indonesia.● Riset Pusham UII di antaranya menemukan pelanggaran hak atas partisipasi, hak-hak ekonomi, sosial, dan ...